Heparin
Research News and Information

Saturday, November 21, 2009

Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment.

29 Nov 2009 Heparin (HP) inhibits pulmonary artery smooth muscle cell (PASMC) growth in vitro and vascular remodeling in vivo. Bârzu et al. (1994) suggested that the antiproliferative effect of HP on rat aortic smooth muscle cell in vitro diminishes with ... Read more...

Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo.

30 Oct 2009 The adhesion of tumor cells with platelets is important in the process of tumor metastasis. A huge work has indicated that anti-adhesion is an effective strategy for metastasis inhibition. In this article, we assess the role of platelet integrin ... Read more...

Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage.

21 Oct 2009 The plasminogen/plasmin system is involved in a variety of normal physiological and pathological processes, including tissue remodelling, angiogenesis and tumour metastasis. Plasminogen activators and receptors for plasminogen/plasminogen activators ... Read more...

Latest indexed articles for 'Heparin'

These are the very latest articles for this heading:

• Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. 29 Nov 2009
• Modified heparins inhibit integrin alpha(IIb)beta(3) mediated adhesion of melanoma cells to platelets in vitro and in vivo. 30 Oct 2009
• Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage. 21 Oct 2009
• Thermodynamic characterization of the interaction between the C-terminal domain of extracellular superoxide dismutase and heparin by isothermal titration calorimetry. 18 Oct 2009
• Phlegmasia cerulea dolens--a rare, life-threatening condition. 12 Oct 2009
• Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes. 10 Oct 2009
• Mast cell-derived particles deliver peripheral signals to remote lymph nodes. 3 Oct 2009
• [Right-sided prosthetic cardiac valve thrombosis: value of cinefluoroscopy in the diagnosis and follow-up of thrombolytic treatment] 30 Sep 2009
• MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis. 29 Sep 2009
• The pulmonary embolism risk score system reduces the incidence and mortality of pulmonary embolism after gastric bypass. 29 Sep 2009
• Automated assay for fondaparinux (Arixtra) on the Dade Behring BCS XP. 29 Sep 2009
• Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 27 Sep 2009
• Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study. 27 Sep 2009
• Incidence and causes of heparin-induced skin lesions. 26 Sep 2009
• Teaching NeuroImages: Reversible bilateral thalamic lesions in vein of Galen thrombosis. 20 Sep 2009
• Expression of concern. 18 Sep 2009
• Compositional analysis of heparin/heparan sulfate interacting with fibroblast growth factor.fibroblast growth factor receptor complexes. 6 Sep 2009
• [Anesthetic management for a patient with heparin-induced thrombocytopenia (HIT) undergoing off-pump coronary bypass surgery using argatroban, a direct thrombin inhibitor] 30 Aug 2009
• Insights into the capillary electrophoresis separation of heparin disaccharides from nuclear magnetic resonance, pKa, and electrophoretic mobility measurements. 30 Aug 2009
• Alzheimer's disease: another target for heparin therapy. 30 Aug 2009

See a longer list of these articles.

Technical information about 'Heparin'

Definition: A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts.

Registry Number: 9005-49-6

Descriptor UI: D006493

Alternative terms: Heparin; Heparinic Acid; Liquaemin; Sodium Heparin; Heparin, Sodium; Heparin Sodium; alpha-Heparin; alpha Heparin;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; biosynthesis; blood; cerebrospinal fluid; chemical synthesis; classification; deficiency; diagnostic use; economics; genetics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; physiology; poisoning; radiation effects; secretion; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists; ultrastructure;

Pharmacological Action: Fibrinolytic Agents; Anticoagulants;

Tree Number: D09.698.373.400;

History Note: /therapeutic use was HEPARIN, THERAPEUTIC 1965